Aug 19, 2025 8:00am EDT ProPhase Labs Announces Filing of Definitive Proxy Statement and New Date for Special Meeting of Shareholders
Aug 13, 2025 8:00am EDT ProPhase Labs Announces Financial Results for the Three and Six Months Ended June 30, 2025
Aug 12, 2025 8:00am EDT ProPhase Labs Announces Full USPTO Approval for Issuance of U.S. Patent Protecting Esophageal Adenocarcinoma Risk Assessment
Aug 11, 2025 8:00am EDT ProPhase Labs Inc. to Present Second Quarter 2025 Financial Results on August 13, 2025
Jul 29, 2025 8:00am EDT ProPhase Labs Announces Special Meeting of Shareholders and Filing of Preliminary Proxy Statement
Jul 23, 2025 8:00am EDT ProPhase Labs Announces Closing of $3 Million Senior Secured Convertible Notes Financing
Jul 21, 2025 8:00am EDT ProPhase Labs Board of Directors Authorizes Management to Explore Strategic Reverse Merger and Approves Crypto Treasury Initiative
Jun 26, 2025 7:30am EDT ProPhase Labs, Inc. Receives Additional 180 Day Extension from Nasdaq to Regain Compliance with Minimum Bid Price Rule
Jun 17, 2025 7:30am EDT ProPhase Labs Announces Successful Study Demonstrating Performance of BE-Smart™ Test in Detecting Esophageal Cancer
Jun 06, 2025 7:00am EDT ProPhase Labs Announces Formation of Clinical Science Advisory Board to Accelerate Commercialization of BE-SmartTM Esophageal Disease Diagnostic Platform
